Abstract

Preview
Heparin-induced thrombocytopenia (HIT) is a drug-induced autoimmune disorder, characterised by thrombocytopenia, an increased incidence of venous, arterial and/or microvascular thrombosis, and auto-antibodies that recognise multimolecular complexes of platelet factor 4 (PF4) bound to heparin or other polyanions1.
Administration of the ChAdOx1 nCoV-19 Astra Zeneca vaccine is frequently followed by flu-like symptoms, such as fatigue, fever, headache, muscle and joint pain, which subside after 1 or 2 days, but in some cases, symptoms can persist beyond the third day. Recently, sinus/cerebral vein thrombosis, pulmonary embolism and splanchnic vein thrombosis, associated with low platelet counts and elevated D-dimer levels, have been reported 5 to 20 days after the first dose of the ChAdOx1 nCoV-19 Astra Zeneca vaccine. This constellation of events has recently been assigned the operative acronym of VITT (vaccine-induced immune thrombotic thrombocytopenia). [ ... ]

References

Downloads

Authors

Maria Costanza Turi Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Francesca Spitaleri Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Anna M. Gori Department of Experimental and Clinical Medicine, University of Florence, Italy

Giustino Parruti Infectious Diseases Unit, “Spirito Santo” Hospital, Pescara, Italy

Angela A. Rogolino Department of Experimental and Clinical Medicine, University of Florence, Italy

Alberto Albani Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Betti Giusti Department of Experimental and Clinical Medicine, University of Florence, Italy

Luciano Agostinone Intensive Care Unit, “Spirito Santo” Hospital, Pescara, Italy

Francesca Cesari Department of Experimental and Clinical Medicine, University of Florence, Italy

Paola Ranalli Centre for Haemorrhagic, Thrombotic and Rare Haematological Diseases, “Spirito Santo” Hospital, Pescara, Italy

Stefano Pulini Haematology Unit, “Spirito Santo” Hospital, Pescara, Italy

Giorgia Di Gioacchino Emergency Unit, “Spirito Santo” Hospital, Pescara, Italy

Roberto Paganelli Department of Medicine and Sciences of Aging, “G. d’Annunzio” University of Chieti-Pescara, and YDA, Institute of Clinical Immunotherapy and Advanced Biological Treatments, Pescara, Italy

Rossella Marcucci Department of Experimental and Clinical Medicine, University of Florence, Italy

  • Abstract viewed - 844 times
  • PDF downloaded - 166 times